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homeostasis through its effects on stem ⁄progenitor cell popula-
tions and differentiation. The effect of Runx1 on epithelial differ-
entiation of the secretory cell lineage of the colon was recently
demonstrated. This study aimed to examine the role of Runx1 in
tumor development in epithelial cells of the gastrointestinal tract.
Conditional knockout mice that lacked Runx1 expression in epithe-
lial cells of the GI tract were generated. These mice were crossed
onto the ApcMin background, killed and their intestinal tumor phe-
notypes were compared with ApcMin Runx1 wild-type control
mice. Apc-wild-type Runx1-mutant mice were also examined for
tumor development. Colons from Runx1 knockout and wild-type
mice were used for genome-wide mRNA expression analyses fol-
lowed by gene-specific quantitative RT-PCR of whole colon and
colon epithelium to identify Runx1 target genes. Runx1 deficiency
in intestinal epithelial cells significantly enhanced tumorigenesis
in ApcMin mice. Notably, epithelial Runx1 deficiency in Apc-wild-
type mice was sufficient to cause tumor development. Absence of
Runx1 was associated with global changes in the expression of
genes involved in inflammation and intestinal metabolism, and
with gene sets indicative of a metastatic phenotype and poor
prognosis. Gene-specific analysis of Runx1-deficient colon epithe-
lium revealed increased expression of genes linked to an expan-
sion of the stem ⁄progenitor cell population. These results identify
Runx1 as a novel tumor suppressor gene for gastrointestinal
tumors and support a role for Runx1 in maintaining the balance
between the intestinal stem ⁄progenitor cell population and
epithelial differentiation of the GI tract. (Cancer Sci 2012; 103:
593–599)
T he human and mouse family of RUNX transcription factorsare composed of three members, RUNX1, RUNX2 and
RUNX3. They function as either transcriptional activators or
repressors depending on the target gene, cell type and the pres-
ence of co-factors. RUNX1 has been implicated in homeostasis
of the hematopoietic stem cell number, as well as in develop-
mental lineage specification, thereby being a critical factor for
hematopoiesis and hematopoietic function.(1,2) In mice, Runx1 is
essential for mammalian development as germline knockouts
(KO) are embryonic lethal due to a complete failure of hemato-
poiesis.(3) In humans, polymorphisms that reduce the binding of
RUNX1 to specific target genes have been associated with sus-
ceptibility to the autoimmune diseases psoriasis, systemic lupus
erythematosus (SLE) and rheumatoid arthritis.(4) Moreover,
RUNX1 is frequently mutated in a common subtype of human
acute myeloid leukemia (AML), where often the rate-limiting
step is formation of mutant fusion genes ⁄proteins that combine
the N-terminal DNA-binding domain of RUNX1 (RHD) with the
full-length activation domains of oncogenes.(5) An example is
the eight twenty-one (ETO) t(8;21) translocation that is present
in approximately 40% of human AML. Notably, these fusion
proteins can function as dominant negative mutants that silencedoi: 10.1111/j.1349-7006.2011.02189.x
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AML.(6,7) An example is derepression of vascular endothelial
growth factor alpha (VEGFA) (an independent prognostic factor
for relapse-free survival in AML) expression in human AML
caused by t(8;21) translocations.(8) Knockin of a Runx1-ETO
fusion transgene causes embryonic lethality in mice similar to
the germline Runx1 KO, further consistent with the fusion pro-
tein having a dominant negative effect on Runx1.(9) Small intra-
genic mutations in RUNX1 have also been reported to exert a
dominant negative effect on RUNX1 function in AML,(10) in
myelodysplasia and familial platelet disorders that can lead to
AML(11–14) in chronic myelomonocytic leukemia that predis-
poses to AML(15) and in T-lymphoblastic lymphomas.(10)
Less is known about the role of RUNX1 in epithelial cancers.
RUNX1 has been reported to be overexpressed in human endo-
metrial cancer and in a mouse skin cancer model.(16) In contrast,
RUNX1 expression has been reported to be downregulated in
some human pituitary cancers,(17) recurrent deletions of RUNX1
were found in human pancreatic adenocarcinomas(18) and homo-
zygous deletions in RUNX1 have been observed in esophageal
adenocarcinoma cell lines and xenografts.(19) RUNX1 downregu-
lation is associated with an increase in FOXO1 expression and
hyperproliferation of breast cancer cells, and has been reported
in hormone-negative breast cancers lacking HER2 amplifica-
tion.(20,21) In the gastrointestinal tract, RUNX1 has been reported
to be downregulated in human gastric cancer cells,(22) and
very recently, Runx1 was identified as an intestinal cancer
susceptibility gene in a Sleeping Beauty transposon-mediated
mutagenesis screen in mice.(23)
The role of another family member, RUNX3, is better charac-
terized in epithelial cancers as it has been reported to act as
either an oncogene or tumor suppressor, with a predominance of
reports describing its function as a tumor suppressor gene in
several human epithelial cancers, such as colorectal, gastric,
esophageal, lung, liver and melanomas.(24–30) In the intestinal
tract, dysregulation of RUNX3 is linked to both inflammation
and cancer. Targeted Runx3 deficiency in mouse leukocytes
leads to inflammatory bowel disease (IBD),(31,32) while hyper-
methylation of the RUNX3 promoter in human intestinal epithe-
lial cells has been observed in ulcerative colitis.(33,34) Silencing
of RUNX3 by hypermethylation has also been reported in human
microsatellite instable/CpG island methylator phenotype (MSI ⁄
CIMP) colorectal cancer (CRC).(35–37) Further, in the gastroin-
testinal (GI) tract, both RUNX1 and RUNX3 are directly
involved in the transforming growth factor beta (TGFb) signal-
ing pathway and act to promote expression of TGFb and its
pathway genes such as BMPs and SMADs.(38) Thus, there is evi-
dence that RUNX1 and RUNX3 expression, function and role in
cancer overlap in some tissues, an observation that has been
further supported by the recent report of single nucleotideCancer Sci | March 2012 | vol. 103 | no. 3 | 593–599
Table 1. Deficiency for Runx1 enhances tumorigenesis in ApcMin mice
Runx1
genotype
Gender n
Colon
tumors
Colon
tumor
incidence (%)
Cecal
tumors
Small
intestine
tumors
Wild type F 30 1.3 ± 1.9 78 0.2 ± 0.6 90 ± 59
Knockout F 31 4.0 ± 2.5* 100 1.0 ± 1.6* 155 ± 63*
Wild type M 36 1.5 ± 1.7 78 0.3 ± 0.6 66 ± 37
Knockout M 38 4.5 ± 3.6* 100 1.2 ± 1.2* 135 ± 60*
ApcMin Runx1 KO mice and littermate ApcMin Runx1 wild-type mice
were killed at 100 days of age. Tumors were isolated and scored as
described in the Materials and Methods section. Two-sided P-values
for tumor counts were determined using the Wilcoxon rank-sum test
comparing gender and age-matched classes produced in the same
genetic crosses. *P-value: <0.05.polymorphisms (SNP) in both RUNX1 and RUNX3 that confer
susceptibility to CRC.(39) Finally, in contrast, a third RUNX
family member, RUNX2, is proposed to largely function as an
oncogene in bone and other cancers.(5,40)
Recently, inducible Mx-Cre-mediated conditional deletion of
Runx1 in mouse colon resulted in decreased expression of Klf4
and goblet cell depletion, demonstrating a role for Runx1 in
regulation of intestinal epithelial differentiation of the secretory
cell lineage.(41) Several lines of evidence indicate that RUNX1
can both positively and negatively interact with Notch
signaling,(42–44) which is important for the proper differentiation
and organization of cells in the GI tract via crosstalk with
Wnt ⁄b-catenin and other canonical signaling pathways.(45,46)
Upregulation of Notch signaling is implicated in both gastric
and colorectal cancers, where it represses goblet cell differentia-
tion.(45,47,48) Inhibition of Notch activity converts proliferative
enterocytes into goblet cells(45) possibly via activation of KLF4
gene expression.(49)
Because of the reported role of RUNX1 in KLF4 signaling
and goblet cell differentiation and its interaction with Notch
signaling activity, here we investigated the role of epithelial
expression of Runx1 in intestinal tumorigenesis. We found that
deficiency of Runx1 significantly enhanced tumorigenesis in
ApcMin mice, thus providing the first direct evidence that Runx1
is a tumor suppressor gene in the mammalian GI tract. Notably,
Apc-wild-type Runx1 knockout mice also developed intestinal
tumors when aged >10 months. Loss of epithelial expression of
Runx1 was associated with increased expression in the whole
colon of genes involved in inflammation and intestinal metabo-
lism, and with gene sets indicative of a metastatic phenotype
and poor prognosis. Gene-specific analysis in Runx1-deficient
colonic epithelial cells revealed increased expression of several
genes implicated in stem cells and Notch signaling.
Materials and Methods
Mice. C57BL ⁄6J (later referred to as wildtype [WT]) and
C57BL ⁄6J-ApcMin mice were obtained from the Jackson Labora-
tory (Bar Harbor, ME, USA). C57BL ⁄6-Runx1 floxed mice(3)
were obtained from Dr Daniel Littman (New York University,
New York, NY, USA). Villin-Cre transgenic mice that are fully
congenic on the C57BL ⁄6 genetic background were obtained
from a colony maintained in our laboratory. The Runx1 floxed
allele was introgressed into an ApcMin strain of mice that carried
a hemizygous copy of the Villin-Cre transgene. For details of
mouse husbandry see the Data S1.
Genotyping. DNA was isolated from tail snips using a Qia-
gen DNA Easy kit (Qiagen, Valencia, CA, USA). The genotype
of the Apc, Villin-Cre and Runx1 loci was determined by PCR
assays as previously described.(3,50,51) The PCR was performed
on an Applied Biosystems GeneAmp 9700 Thermal Cycler
(Applied Biosystems, Foster City, CA, USA).
Oligonucleotide microarray and data analysis. Two-color
microarray-based gene expression analysis was carried out using
Agilent 4x44K whole mouse genome microarrays (G4122F;
Agilent Technologies, Wilmington, DE, USA). This array
includes more than 41 000 mouse genes and transcripts. Per
sample, 500 ng of RNA was spiked, labeled, amplified and
hybridized using Agilent reagents, according to Agilent Gene
Expression oligo microarrays protocol (version 5.0.1). For each
group (Villin-Cre transgenic and non-transgenic), half of the
samples were labeled with Cy3 and half of the samples with
Cy5 to prevent bias of the data due to labeling with these fluo-
rescent dyes. Arrays were scanned using an Agilent Microarray
Scanner, and the intensity of fluorescent images was quantified
using Agilent Feature Extraction software (version 9.5.1). Pre-
processing of data, quality checks and significance analysis were
all performed as previously described.(52) Differential expression594of genes was quantified by the moderated t-statistic. Gene Set
Enrichment Analysis (GSEA) was used as a computational
method to identify sets of genes with coordinate differences
in gene expression (GSEA v2.0, http://www.broad.mit.edu/
gsea/).(53,54) Gene sets analyzed were obtained from the Molecu-
lar Signatures Database (MSigDB_v2.5, http://www.broad.
mit.edu/gsea/msigdb/index.jsp) using settings as previously
described.(55) Gene expression data has been submitted to the
Gene Expression Omnibus. Accession number GSE34292.
Statistical analysis. Two-sided P-values for tumor counts
were determined using the Wilcoxon rank-sum test comparing
gender and age-matched classes produced in the same genetic
crosses.
Histopathology, immunohistochemistry, RNA extraction,
isolation of intestinal epithelium, qRT-PCR and tumor analysis
(See Data S1, Supplemental Methods).
Results
Phenotype of intestinal-specific Runx1-deficient mice.
Homozygous Runx1 floxed mice expressing the intestinal-speci-
fic Villin-Cre transgene were compared with Villin-Cre-negative
littermates. We observed no differences in survival, gender ratio,
growth, adult size or weight. Formalin-fixed intestinal tissues
from all regions were examined using histopathological analysis
and no differences were discernable. Tissues were further tested
via immunohistochemistry for Ki-67 (cell proliferation), lyso-
zyme (Paneth cells), Muc2 and Alcian blue (goblet cells) and no
differences were observed (Fig. S1). Knockout of Runx1 expres-
sion was confirmed using immunohistochemistry (Fig. S2) and
qRT-PCR (Fig. S3).
Runx1 deficiency results in enhanced tumorigenesis in ApcMin
mice. We tested the role of Runx1 in intestinal tumorigenesis
by creating ApcMin mice that were homozygous for a Runx1 flo-
xed allele and were either positive or negative for the intestinal-
specific Villin-Cre transgene. Direct comparison of littermate
test (Villin-Cre positive, Runx1 KO) and control mice (Villin-
Cre negative, Runx1 wild type) provided strong evidence that
Runx1 is a tumor suppressor in the mouse intestine. Intestinal
tumor multiplicity in the Runx1 KO mice was threefold higher
in the colon (P < 0.05), greater than fourfold higher in the
cecum (P < 0.05) and almost twofold higher in the small intes-
tine (P < 0.05). More than one-third of the Runx1 KO mice
developed more than 200 tumors, with the highest tumor count
at 321 tumors. In contrast, the majority of Runx1 wild-type mice
developed <100 tumors and <5% developed more than 200
tumors (Table 1). We also measured tumor sizes and found that
tumors in the small intestine of Runx1 KO mice were larger than
Runx1 wild-type mice, with the difference strongest in the ileum
(Fig. S4). All of these phenotypic differences were observed
in both male and female mice. All tumors examined usingdoi: 10.1111/j.1349-7006.2011.02189.x
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histopathology were adenomas, and thus resemble the same
types of tumors normally observed in ApcMin mice. Moreover, in
contrast to ApcMin mice that do not normally develop gastric
tumors, approximately 10% of ApcMin Runx1 KO mice devel-
oped 1, 2, 3 or 4 small tumors in the pyloric canal (Fig. S5A).
Histological analysis revealed the tumors to be small, polypoid
adenomas in the terminal pylorus or at the junction of the pylo-
rus with the duodenum (Fig. S5B).
Runx1 deficiency results in tumorigenesis in Apc+ ⁄ + mice. We
aged a group of approximately 20 Apc+ ⁄ + Runx1 KO and Runx1
wild-type mice to approximately 12 months to evaluate the
intestinal phenotype of Runx1 deficiency alone. We found that
approximately 33% of Runx1 KO mice developed 1, 2 or 3
tumors in the duodenum, while no tumors were observed in
Runx1 wild-type control mice (Table 2). All tumors examined
using histopathology were adenomas. Four tumors were exam-
ined using light microscopy; all were relatively small, approxi-
mately 3–4 mm diameter. All tumors were classified as sessile
or flat adenomas, with one tumor showing a tendency towards
pedunculation (fibrovascular expansion of the lamina propria) at
one margin. Three tumors overlay, wholly or in part, the under-
lying Brunner’s glands, and in places the epithelial component
appeared to be contiguous with the Brunner’s glands (Fig. S6A).
No evidence of local invasion or metastasis was observed.
Immunohistochemical analysis indicated that more than half of
these duodenal tumors demonstrated upregulation of b-catenin
protein (Fig. S6B).
Gene expression analysis of epithelial Runx1 KO and Runx1
WT colon. To identify epithelial Runx1-mediated alterations in
gene expression in the mouse GI tract, RNA was isolated from
the medial colon of Runx1 KO mice and from gender and age-Table 2. Deficiency for Runx1 causes duodenal tumors in Apc+ ⁄ + mice
Genotype n Mean age Incidence (%)
Tumor
multiplicity
Runx1 wild type 10 12 months 0 0
Runx1 knockout 9 12 months 33 0.7
Runx1 knockout mice and littermate wild-type mice were aged to
approximately 12 months, killed and the tissues were formalin fixed.
The entire intestinal tract was examined for tumors as described in
the Materials and Methods section.
Fig. 1. Change in gene expression in Runx1 knockout (KO) whole colon.
qRT-PCR assay are described in the Materials and Methods section. Each
that measured fold differences in the mRNA expression of specific target
Apc+ ⁄ + Runx1 KO and Runx1 wild-type mice. All tissues were from adul
isolated from 1-cm sections of colon from the same region of the distal co
each assay were performed for each matched pair of mRNA (KO versus w
pair of mRNA). At least two matched pairs of mRNA were tested for e
mRNA. To be included in this figure, genes met the flowing criteria: (i) th
showed at least a twofold difference); and (ii) each gene showed a chan
mRNA (i.e. all upregulated or all downregulated in each matched pair of
Fijneman et al.matched Runx1 wild-type littermate control mice. Gene expres-
sion analysis was then carried out using Agilent 4x44K whole
mouse genome microarrays, followed by quantitative RT-PCR
of select target genes. Examination of the 300 most significant
genes in the array study identified several functional clusters of
genes, with the largest group consisting of genes involved in
inflammation, immune responses and the hematopoietic system.
This group included Duoxa2, C4bp, Hemt1, Slc7a11, Cxcl14,
Crisp3, Cd55, Clca3, Tnip3, Indo, Pou2af1, Runx2, Mst1, Immu-
noglobulins (many), Cd300lf, Rorc, Cd40, Ehf, Mmp9, Cd2,
Cebpd, Retnlg, Il1rl1, Ccl8, Icos, Nfkbiz, Ccr10, Il1rl2, Gpr17,
Cxcr4 and Tnfrsf13b. The second largest group of Runx1 target
genes was comprised of genes implicated in intestinal metabo-
lism, including several lipases and genes associated with goblet
cell function. This group included Mptx, Pnliprp2, Retnlb,
Pnliprp1, Clps, Es1, Clca3, Tgn, Slc1a1, Itlna, Spink4, Scin,
Ero1l, Pax6, Mmp9, Hsp110 and Retnlg. Figure S7 lists the
most significant differentially expressed genes. Differential
expression was confirmed by qRT-PCR analysis (Fig. 1). Nota-
bly, for all six genes out of the top seven genes (ranked by
P-value) for which reliable primers could be generated, differen-
tial expression was confirmed, thereby validating the array data.
Gene set enrichment analysis. Changes in biological pro-
cesses are accompanied by coordinate variation in expression of
sets of genes. Gene Set Enrichment Analysis (GSEA) was
applied to identify associations with gene sets differentially
expressed between Runx1 KO and Runx1 WT colon (Table 3).
Interestingly, a significant association was found with the gene
set that distinguishes pediatric acute myeloid leukemia (AML)
subtype inv16[CBFb-MYH11] (gene set #2)(56) thereby illustrat-
ing that genes expressed on mutation of CBFb in human AML
overlap significantly with the genes expressed on epithelial
Runx1 deficiency in mouse colon. Because Runx1 binds CBFb
to form a functional heterodimeric transcription factor,(9) these
data support the validity of our approach. The significant associ-
ation with the ‘tryptophan metabolism’ gene set (gene set #9) is
in accordance with alteration of expression of genes involved in
inflammation and immune responses that might lead to IBD and
increased CRC risk.(57) The association with the ‘peroxisome
proliferator-activated receptor (PPAR) signaling pathway’ (gene
set #11) is in accordance with the alteration of expression of
genes involved in intestinal metabolism,(58) and also predisposes
to increased CRC risk(50) Moreover, two gene sets indicate thatList of 20 Runx1 target genes examined using qRT-PCR. Details of the
bar represents the mean and standard error of multiple experiments
genes in whole colon tissue from gender and aged matched pairs of
t mice generally approximately 100 days of age, and the mRNA were
lon. All mRNA values were normalized to 18S values. Four replicates of
ild type) and these sets of assays were repeated at least twice for each
ach gene, with most genes tested in at least three matched pairs of
e mean fold difference was at least 1.5 (and almost all of the 20 genes
ge in gene expression in the same direction in each matched pair of
mRNA).
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Table 3. Gene Set Enrichment Analysis (GSEA) gene sets ‘UP or DOWN’ in Runx1 knockout compared with Runx1 wild type (FWER < 0.05)
# Collection† Name of Gene Set†
Size (number
of genes)
ES NES
FDR FWER
q-value P-value
Gene sets ‘UP’ in Runx1 knockout compared with Runx1 wild type (FWER < 0.05)
1 Curated (c2) BOQUEST_CD31PLUS_VS_CD31MINUS_DN 155 0.55 2.40 0 0
2 Curated (c2) ROSS_CBF_MYH 32 0.68 2.18 0.009 0.012
3 Curated (c2) BRCA_PROGNOSIS_NEG 68 0.58 2.17 0.009 0.017
4 Curated (c2) EMT_UP 43 0.62 2.16 0.007 0.018
5 Curated (c2) AGEING_KIDNEY_UP 203 0.48 2.13 0.009 0.028
6 Curated (c2) AGEING_KIDNEY_SPECIFIC_UP 103 0.53 2.13 0.007 0.029
7 Curated (c2) BRUNO_IL3_DN 44 0.61 2.11 0.009 0.039
8 Curated (c2) PRMT5_KD_UP 126 0.51 2.10 0.008 0.041
Gene sets ‘DOWN’ in Runx1 knockout compared with Runx1 wild type (FWER < 0.05)
9 Curated (c2) TRYPTOPHAN_METABOLISM 24 )0.72 )2.16 0.004 0.010
10 Curated (c2) HCC_SURVIVAL_GOOD_VS_POOR_UP 89 )0.52 )2.08 0.006 0.029
11 Curated (c2) HSA03320_PPAR_SIGNALING_PATHWAY 51 )0.57 )2.05 0.006 0.044
†Obtained from the Molecular Signatures Database (MSigDB_v2.5, http://www.broad.mit.edu/gsea/msigdb/index.jsp). ES, GSEA enrichment score;
FDR, false discovery rate; FWER, family wise error rate; NES, GSEA normalized enrichment score.Runx1 deficiency is associated with expansion of a pluripotent
(stem) cell population at the expense of more differentiated cells
(gene set #1(59) and #7(60)) while other gene sets indicate that
Runx1 deficiency is associated with more metastases (gene set
#4(61)) and poor prognosis in breast cancer (gene set #3(62)) and
hepatocellular cancer (gene set #10). Taken together, these data
imply that tumor-free colons from Runx1-deficient mice express
gene profiles related to expanded stem ⁄pluripotent progenitor
cell populations compared with colon from Runx1 wild-type
mice.
Gene-specific expression analysis of Runx1 KO and Runx1 WT
colon epithelium. Considering the reported interactions between
Runx1 and Notch signaling activity combined with the whole
colon GSEA results indicating putative effects of Runx1 on reg-
ulation of the size of the stem ⁄progenitor cell compartment, we
decided to examine expression of individual genes associated
with intestinal stem ⁄progenitor cells and intestinal differentia-
tion. Colon epithelium was isolated from Runx1 KO and Runx1
WT colon and gene expression was analyzed using qRT-PCR
for genes analyzed in the whole colon plus the putative stem cell
marker Aldh1a1, and the Notch pathway genes Notch1, Jag1
and Hes1 (Fig. 2). Our data from the analysis of Runx1-deficient
colon epithelium confirmed the expression patterns for many of
the whole colon genes, but also revealed increased expression of
Aldh1a1, Notch1, Jag1 and Hes1, thereby supporting a role for
Runx1 in direct regulation of the expression of Notch signaling
pathway genes.
Discussion
Here we showed that Runx1 is a novel tumor suppressor gene in
the GI tract. Conditional ablation of Runx1 expression in ApcMin
mice caused a significant increase in the number of tumors, in
all regions of the intestine, and in both male and female mice.
At a low frequency we also observed small tumors in the pyloric
canal leading from the stomach to the duodenum, a type of
tumor that is not normally seen in ApcMin mice at 100 days.(63)
It is very possible that these gastric tumors arose from the com-
bination of Apc deficiency and excision of Runx1 in a rare popu-
lation of progenitor cells that express villin in the antral glands
of the pylorus.(64,65) Moreover, Runx1 deficiency also caused the
development of duodenal tumors in Apc wild-type mice that
were aged to approximately 12 months. To examine the effects
of Runx1 epithelial deficiency on gut homeostasis preceding
colon tumor development, genome-wide mRNA expression pro-
files of colon from Runx1 KO mice were compared with Runx1
WT mice. The largest clusters of differentially expressed genes596were implicated in: (i) inflammation, immune responses and
hematopoeitic processes; and (ii) intestinal metabolism, such as
lipases, goblet cell proteins and transporters. Virtually all of the
most significantly regulated genes identified (ranked by P-val-
ues) were confirmed using qRT-PCR, lending confidence to the
array data (Fig. 1). Analysis of the differential expression of
gene sets using GSEA revealed a significant association with
genes expressed on mutation of CBFb, a key partner of RUNX1
in transcriptional activation, further supporting the validity of
our approach. Other gene sets confirmed the effects of Runx1
deficiency on inflammation and immune responses and on
intestinal metabolism (Table 3).
Two of the top genes implicated in inflammation and immune
cell responses are involved in complement activity: C4bp and
Cd55,(66) which inhibit complement by differing mecha-
nisms.(67,68) As both C4bp and Cd55 are upregulated in Runx1
KO colon, these changes suggest that Runx1 promotes comple-
ment recruitment and activity. C4bp has been reported to be
increased in the plasma of colon cancer patients,(55) while Cd55
expression has been reported to be increased in the intestine of
ApcMin mice(69) and in human colorectal cancer(70) where its
expression is associated with tumor recurrence, metastasis and a
poor prognosis.(71) Thus, Runx1 inhibition of C4bp and Cd55
expression in the colon is consistent with its tumor-suppressive
role in the GI tract.
A second large cluster of Runx1 target genes in mouse colon
are involved in intestinal cell metabolism, in particular genes
expressed in goblet and Paneth cells. An example is Retnlb, resi-
stin-like beta, which is expressed in intestinal goblet cells where
it is involved in lipid metabolism, host defense and immune
responses.(72) Retnlb expression is increased in inflammatory
bowel disease, gastric cancer and colorectal cancer, where it is
associated with upregulation of interferon (IFN) gamma activ-
ity.(73,74) Retnlb was also reported to be highly upregulated in
tumors isolated from ApcMin mice.(75) Our gene expression stud-
ies indicated that Retnlb expression is inhibited by Runx1 in
mouse colon (Figs 1,2). Two other genes involved in intestinal
metabolism that are upregulated in Runx1 KO colon are Ang4
(angiogenin 4) and Spink4 (serine peptidase inhibitor, Kazal
type 4). Both of these genes have been described as transcrip-
tional targets of b-catenin signaling in Paneth cells whose
expression is upregulated in mouse Apc) ⁄ ) cells,(76,77) thereby
connecting Runx1 to Wnt ⁄b-catenin signaling.
In addition to the putative link between Runx1 and Wnt ⁄
b-catenin signaling, Runx1 has also been connected to Notch sig-
naling. Recently, Runx1 was reported to be implicated in regula-
tion and differentiation of the intestinal secretory cell lineage,doi: 10.1111/j.1349-7006.2011.02189.x
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Fig. 2. Changes in gene expression in Runx1 knockout (KO) colon
epithelial cells. List of nine Runx1 target genes examined using qRT-
PCR. Details of the qRT-PCR assay are described in the Materials and
Methods section. Each bar represents the mean and standard error of
multiple experiments that measured fold differences in the mRNA
expression of specific target genes in colon epithelial tissue from
gender and age-matched pairs of Apc+ ⁄ + Runx1 KO and Runx1 wild-
type mice. All tissues were from adult mice generally approximately
100 days of age, and the mRNA were isolated from 1-cm sections of
colon from the same region of the distal colon. All mRNA values were
normalized to 18S values. Four replicates of each assay were
performed for each matched pair of mRNA (KO versus wild type) and
these sets of assays were repeated at least twice for each pair of
mRNA). At least two matched pairs of mRNA were tested for each
gene with most genes tested in at least three matched pairs of mRNA.
To be included in this figure, genes met the flowing criteria: (i) the
mean fold difference was at least 1.5 (and almost all of the nine
genes showed at least a twofold difference); and (ii) each gene
showed a change in gene expression in the same direction in each
matched pair of mRNA (i.e. all upregulated or all downregulated in
each matched pair of mRNA).identifying the Kruppel like factor 4 (Klf4) gene as a target of
Runx1.(40) Klf4 is a zinc-finger transcription factor that is
strongly expressed in terminally differentiated intestinal epithe-
lial cells. Klf4 has also been associated with differentiation of
the secretory cell lineage and with inhibition of intestinal cell
proliferation via blocking progression of the cell cycle.(78,79)
Haploinsufficiency for Klf4 enhanced tumorigenesis in the
ApcMin mouse(80) and KLF4 has been reported to be downregu-
lated in human colorectal cancer.(81) In the GI tract, expression
of KLF4 is inhibited by Notch signaling and inhibition of Notch
signaling results in a shift of intestinal crypt cells in favor of a
goblet cell fate and away from an absorptive cell fate.(48,80)
Moreover, it is known that Hes1, a key Notch pathway gene,
represses expression of Math1, a gene required for goblet cell
differentiation.(82) In the present study we confirmed using qRT-
PCR that Runx1 positively regulated expression of Klf4 in mouse
colon (Fig. 1) and found that Runx1 appeared to regulate expres-Fijneman et al.sion of Notch pathway genes (Notch1, Jag1 and Hes1) in colon
epithelial cells (Fig. 2). Taken together, these data suggest that
positive regulation of Klf4 by Runx1 might result from inhibition
of Notch signaling and thus de-repression of Klf4 by Notch. Of
interest, Runx3 has been reported to directly interact with Notch1
and suppress Notch signaling in hepatocellullar cancer
cells,(83,84) hence it is possible that Runx3 and Runx1 exert simi-
lar suppressive effects on Notch signaling in the intestinal tract.
Both Wnt and Notch signaling pathways are involved in regu-
lation of the stem- ⁄pluripotent progenitor cell compartment.(45)
Moreover, Runx1 itself has been described as a regulator of
stem cell proliferation, with isoform-specific positive and nega-
tive effects on the cell cycle.(85) Therefore, one mechanism
through which Runx1 might exert its suppressive effects on
tumor development is by limiting expansion of the stem- ⁄pluri-
potent progenitor cell compartment. Aldh1a1 (Aldh1) was
recently implicated as a putative biomarker for colon cancer
stem cells.(86) In the present study, Runx1 negatively regulated
expression of Aldh1a1 in colonic epithelial cells (Fig. 2). This
finding is consistent with a putative role for Runx1 in regulation
of the stem ⁄progenitor population, further supported by Runx1
negative regulation of Notch1, Jag1 and Hes1 in colonic epithe-
lial cells (Fig. 2).
Moreover, GSEA revealed significant associations of Runx1
deficiency with gene sets representing an increased metastatic
phenotype (Table 3, gene set #4) and poor prognosis in breast
and hepatocellular cancer (Table 3, gene sets #3 and #10), phe-
nomena that might be related to (cancer) stem cell characteris-
tics. Considered together, these data imply that colon from
Runx1 KO mice expresses genes involved in expanded (cancer)
stem ⁄pluripotent progenitor cell populations compared with
Runx1 wild-type mice.
In summary, we have provided the first evidence that Runx1
is a tumor-suppressor gene in the mammalian GI tract. Defi-
ciency for Runx1 in intestinal epithelial cells significantly
enhanced tumorigenesis in ApcMin mice, while Runx1 deficiency
alone was sufficient to cause tumorigenesis in Apc-wild-type
mice. We have identified a set of Runx1 target genes in mouse
colon indicative of changes in gut homeostasis, that is, genes
involved in inflammation and intestinal metabolism, which are
known to increase the risk of tumor development. Moreover, the
results of the present study support a role for Runx1 in suppress-
ing Notch pathway signaling, a finding that is consistent with
Runx1 regulating the stem cell ⁄progenitor cell compartment in
intestinal crypts and consequent Notch-mediated effects on
intestinal cell differentiation and proliferation. Further studies
are required to explore the genetic and epigenetic status and role
of Runx1 in human colorectal cancers.
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